Speedus (SPDE) Surges On FDA Clearance
Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), received FDA clearance to market its new Signal X6(TM) device. Zargis also announced the delivery of seven Signal X6 devices to the U.S. Army for deployment in six Department of Defense medical facilities.
Shares are up 98% today.
Signal X6 is noninvasive, easy to use and simultaneously records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, for locations where a cardiac specialist is not immediately available for consultation, transmitted through the Internet for remote evaluation. Signal X6 and our recently launched Zargis Cardioscan(TM) device were both designed for user-friendly digital heart sound analysis. The configuration of the Signal X6 provides a unique telemedicine resource in situations where evaluations would benefit from high fidelity multi-channel synchronous recordings.
Shares are up 98% today.
Signal X6 is noninvasive, easy to use and simultaneously records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, for locations where a cardiac specialist is not immediately available for consultation, transmitted through the Internet for remote evaluation. Signal X6 and our recently launched Zargis Cardioscan(TM) device were both designed for user-friendly digital heart sound analysis. The configuration of the Signal X6 provides a unique telemedicine resource in situations where evaluations would benefit from high fidelity multi-channel synchronous recordings.
You May Also Be Interested In
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- When Will Rosetta Genomics (ROSG) Crash From its 1346% Gain?
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
